Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 51.00 as of 2026-10-02T20:30:52.397Z.
Consensus retrieved: 2026-10-02T16:51:12.139Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-02T20:30:52.397Z.
Quote observation: 2026-10-02T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 68d974e15a8266ddc93c7b2c8b7bae87600a98df9f9341d8623e7366e780aece
Forward PE Ratio (51.00) = Dated Quote Price ($273.04) / Consensus Forward EPS ($5.35)
FORWARD PE RATIO
51.00
SECTOR MEDIAN · HEALTHCARE
18.80
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+171.28%
vs the sector median at left
Illumina, Inc.
Market Cap
$41.31B
Forward PE Ratio
51.00
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Illumina, Inc. (ILMN) | $41.31B | 51.00 |
| IDEXX Laboratories, Inc. (IDXX)vs › | $40.89B | 35.13 |
| Waters Corporation (WAT)vs › | $41.75B | 29.18 |
| IQVIA Holdings Inc. (IQV)vs › | $42.50B | 19.91 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $46.04B | 20.04 |
| Humana Inc. (HUM)vs › | $46.63B | 42.41 |
| Agilent Technologies, Inc. (A)vs › | $47.38B | 27.06 |
| Becton, Dickinson and Company (BDX)vs › | $48.72B | 13.37 |
| Edwards Lifesciences Corporation (EW)vs › | $49.03B | 28.37 |
| Biogen Inc. (BIIB)vs › | $32.49B | 17.71 |
Trailing P/E
50.9
reported TTM EPS
Forward P/E
51.0
consensus EPS · fiscal year ending 2026-12-28
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $5.35 implies -0.2% EPS decline vs the reported trailing $5.36.
At the dated quote price of $273.04, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-28 | $5.35 | $5.33 – $5.39 | 12 | 51.0x |
| 2027-12-28 | $6.08 | $5.84 – $6.54 | 12 | 44.9x |
| 2028-12-28 | $7.02 | $6.67 – $7.72 | 7 | 38.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
